Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Coya Therapeutics (COYA) over the last 4 years, with Q3 2025 value amounting to $19137.0.

  • Coya Therapeutics' Cash from Financing Activities rose 13397.18% to $19137.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 6810.69%. This contributed to the annual value of $16.0 million for FY2024, which is 5829.07% down from last year.
  • Per Coya Therapeutics' latest filing, its Cash from Financing Activities stood at $19137.0 for Q3 2025, which was up 13397.18% from $19137.0 recorded in Q1 2025.
  • In the past 5 years, Coya Therapeutics' Cash from Financing Activities registered a high of $24.2 million during Q4 2023, and its lowest value of -$104071.0 during Q4 2022.
  • Over the past 4 years, Coya Therapeutics' median Cash from Financing Activities value was $630450.5 (recorded in 2024), while the average stood at $5.3 million.
  • As far as peak fluctuations go, Coya Therapeutics' Cash from Financing Activities soared by 2332909.55% in 2023, and later crashed by 9845.89% in 2025.
  • Quarter analysis of 4 years shows Coya Therapeutics' Cash from Financing Activities stood at -$104071.0 in 2022, then skyrocketed by 23329.1% to $24.2 million in 2023, then crashed by 59.91% to $9.7 million in 2024, then tumbled by 99.8% to $19137.0 in 2025.
  • Its Cash from Financing Activities was $19137.0 in Q3 2025, compared to $19137.0 in Q1 2025 and $9.7 million in Q4 2024.